AIM IMMUNOTECH INC.

AIM

CIK 0000946644 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$21K
↓-53.3% -$24Kvs FY2024 (Q4)
Gross Profit
$21K
↓-53.3% -$24Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
34/100
  • Profitability
    100ROIC 482.2% (10% = solid, 20%+ = moat)
  • Liquidity
    1Current Ratio 0.53 (above 1.5 = solid)
  • Leverage
    100D/E -0.46 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -53.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -9411.5% · trend -2688.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock-based comp (TTM)
$60K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$6M
everything owned
Total liabilities
$16M
everything owed
Stockholders' equity
$-10M
shareholder claim
Net debt
$1M
LT debt minus cash

Recent performance · 64 quarters

Revenue↓-53.3% -$24K
$21K
Net Income↑+11.2% +$416K
$-3M
Free Cash Flow↑+51.0% +$2M
$-2M
Operating Margin↑+3414.2pts
-9411.5%

Drill down